Biopharmaceutical manufacturing companies focus on producing biological products derived from living organisms. This sector includes firms engaged in developing drugs, vaccines, and therapeutics harnessing biotech innovations. With a growing emphasis on personalized medicine and biologics, companies are increasingly developing treatments targeting specific diseases. The market is moving towards sustainability and advanced manufacturing techniques, including automation and enhanced testing protocols, to meet rising demand. Furthermore, advancements in cell and gene therapies are shaping the future, allowing for innovative health solutions not previously possible.

The list features 24 biopharmaceutical manufacturing companies known for their innovative therapeutic solutions and strong market presence. These companies range from small firms with specialized niches to large multinationals with extensive portfolios. Headquarters span several continents, showcasing the global nature of this industry. Founded in various decades, the companies have expertise in vaccine production, biologics, and more niche therapies, illustrating a rich tapestry of specialization and clinical focus across diverse healthcare territories.

Continue reading to learn more about top biopharmaceutical manufacturing companies.

Top 24 Biopharmaceutical Manufacturing Companies

1. Octapharma

• Website: octapharma.com
• Ownership type: Private
• Headquarters: Lachen, Schwyz, Switzerland
• Employee distribution: Austria 24%, United States (USA) 23%, Sweden 15%, Other 38%
• Founded year: 1983
• Headcount: 10001+
• LinkedIn: octapharma

Octapharma AG, founded in 1983 and headquartered in Lachen, Switzerland, is a privately owned pharmaceutical company that specializes in the development and production of human proteins derived from plasma and cell lines. The company operates in three primary therapeutic areas: haematology, immunotherapy, and critical care. Octapharma is recognized as the largest privately owned plasma fractionator globally, with a significant presence in 32 countries and products available in 118 countries. Their manufacturing process is characterized by stringent quality control measures, ensuring the safety and efficacy of their medicines. Octapharma also runs over 190 plasma donation centers in the United States and additional centers in Europe, which are crucial for sourcing the plasma needed for their therapies. The company is dedicated to advancing human health through innovative solutions and actively engages with patient communities to support their needs.

2. Seattle Genetics

• Website: seattlegenetics.com
• Ownership type: Private
• Headquarters: Bothell, Washington, United States (USA)
• Founded year: 1998
• Headcount: 1001-5000
• LinkedIn: seattle-genetics

Seattle Genetics, founded in 1998 and based in Bothell, Washington, is a biopharmaceutical company that focuses on developing and manufacturing innovative therapies for cancer treatment. The company is particularly known for its pioneering work in antibody-drug conjugates (ADCs), which combine targeted antibodies with potent cytotoxic drugs to deliver treatment directly to cancer cells. This approach aims to minimize damage to healthy cells while maximizing therapeutic efficacy. Seattle Genetics has a robust pipeline of products and is actively engaged in clinical trials to bring new therapies to market. Their commitment to research and development is evident in their collaborations with various healthcare organizations and their focus on addressing unmet medical needs in oncology. With a workforce of over 2,000 employees, Seattle Genetics continues to play a vital role in advancing cancer treatment options.

3. PROBIOMED S.A. de C.V.

• Website: probiomed.com.mx
• Ownership type: Corporate
• Headquarters: Mexico
• Employee distribution: Mexico 99%
• Latest funding: May 2022
• Founded year: 1970
• Headcount: 501-1000
• LinkedIn: probiomedmx

PROBIOMED S.A. de C.V. is a Mexican biopharmaceutical company established in 1970. The company is dedicated to the research, development, manufacturing, and commercialization of pharmaceutical products that cater to human health needs. With a workforce of approximately 657 employees, PROBIOMED focuses on creating high-technology biopharmaceuticals aimed at treating serious diseases that have significant social and economic impacts. Their product offerings include therapies for conditions such as cancer, chronic kidney disease, rheumatoid arthritis, multiple sclerosis, and diabetes. The company’s portfolio features a variety of biopharmaceuticals, including monoclonal antibodies, cytokines, fusion proteins, and recombinant vaccines. PROBIOMED is committed to improving patient access to effective treatments and has been a key player in the Mexican healthcare landscape for over five decades.

4. FUJIFILM Diosynth Biotechnologies

• Website: fujifilmdiosynth.com
• Ownership type: Corporate
• Headquarters: Morrisville, North Carolina, United States (USA)
• Employee distribution: Denmark 43%, United States (USA) 40%, United Kingdom (UK) 17%
• Latest funding: $890.0M, August 2019
• Founded year: 2011
• Headcount: 1001-5000
• LinkedIn: fujifilm-diosynth-biotechnologies

FUJIFILM Diosynth Biotechnologies is a biotechnology company based in Morrisville, North Carolina, specializing in contract development and manufacturing services for biologics, vaccines, and advanced therapies. Founded in 2011, the company has quickly established itself as a key player in the biopharmaceutical industry. They partner with pharmaceutical and biotechnology firms, providing expertise in cGMP processes to ensure the safe and effective delivery of products. With a workforce of over 5,000 employees distributed across facilities in the United States, Denmark, the United Kingdom, and Japan, FUJIFILM Diosynth Biotechnologies supports clients through all phases of drug development, from pre-clinical studies to commercialization. Their investment in expanding manufacturing capabilities, including a recent $890 million funding round, underscores their commitment to innovation and growth in the biopharmaceutical sector.

5. Samsung Bioepis

• Website: samsungbioepis.com
• Ownership type: Corporate
• Headquarters: Yeonsu-Gu, Incheon, South Korea
• Employee distribution: South Korea 91%, Netherlands 3%, Other 6%
• Latest funding: January 2022
• Founded year: 2012
• Headcount: 501-1000
• LinkedIn: samsungbioepis

Samsung Bioepis, based in Yeonsu-Gu, Incheon, South Korea, is a biopharmaceutical company that focuses on the development and commercialization of biosimilar medicines. Established in 2012, the company aims to improve patient access to high-quality biologic therapies, particularly in the fields of immunology and oncology. With a workforce of approximately 1,584 employees, Samsung Bioepis has built a strong reputation for its commitment to quality and innovation. The company has developed a rapidly expanding portfolio of biosimilars, including products that have received approvals from major regulatory authorities such as the FDA and the European Commission. Their partnerships with organizations like Biogen and Organon further enhance their capabilities in bringing these medicines to market. Samsung Bioepis is also actively exploring new therapeutic areas, including ophthalmology and gastroenterology, demonstrating their ongoing commitment to addressing unmet medical needs.

6. Bharat Biotech

• Website: bharatbiotech.com
• Ownership type: Venture Capital
• Headquarters: Hyderabad, Telangana, India
• Employee distribution: India 99%
• Latest funding: Other (Grant), $14.1M, June 2020
• Founded year: 1996
• Headcount: 1001-5000
• LinkedIn: bharat-biotechil

Bharat Biotech International Limited, founded in 1996 and based in Hyderabad, Telangana, India, is a biotechnology company focused on the development and manufacturing of vaccines and biotherapeutics. With a workforce of approximately 1,800 employees, the company has made significant strides in addressing infectious diseases, particularly in developing regions. Bharat Biotech has developed over 220 patents and has delivered more than 9 billion vaccine doses globally. Their product range includes notable vaccines such as COVAXIN, an indigenous COVID-19 vaccine, and ROTAVAC, a rotavirus vaccine. The company operates manufacturing facilities that are approved by regulatory bodies like the USFDA and WHO, ensuring compliance with global standards. Bharat Biotech's mission is to provide affordable, safe, and high-quality healthcare solutions, with a strong emphasis on research and development to tackle pressing health challenges. In June 2020, they received a grant of $14.1 million, which underscores their ongoing commitment to innovation in the biopharmaceutical field.

7. Kedrion Biopharma

• Website: kedrion.com
• Ownership type: Private Equity
• Headquarters: Fort Lee, New Jersey, United States (USA)
• Employee distribution: Italy 49%, United States (USA) 27%, United Kingdom (UK) 14%, Other 11%
• Latest funding: September 2022
• Founded year: 2001
• Headcount: 1001-5000
• LinkedIn: kedrion-biopharma

Kedrion Biopharma is a biopharmaceutical company founded in 2001, with its headquarters in Fort Lee, New Jersey. The company specializes in the collection and fractionation of blood plasma to produce and distribute therapies aimed at treating rare and debilitating diseases, such as coagulation disorders and immunodeficiencies. Kedrion operates on a global scale, with production facilities in multiple countries and a network of plasma collection centers in the United States and the Czech Republic. The company has expanded its capabilities through strategic acquisitions, including the purchase of Bio Products Laboratory in 2022, enhancing its portfolio of plasma-derived medicines. Kedrion is dedicated to maintaining high industry standards and ensuring the safety and quality of its products, which are distributed in over 100 countries worldwide.

8. Dendreon

• Website: dendreon.com
• Ownership type: Corporate
• Headquarters: Seal Beach, California, United States (USA)
• Employee distribution: United States (USA) 97%, Other 3%
• Latest funding: $819.9M, June 2017
• Founded year: 1992
• Headcount: 501-1000
• LinkedIn: dendreon

Dendreon Pharmaceuticals LLC, founded in 1992 and based in Seal Beach, California, is a biotechnology firm that specializes in immunotherapy for cancer treatment. The company is best known for its flagship product, Provenge (sipuleucel-T), which is the first FDA-approved immunotherapy that utilizes a patient's own immune cells to treat advanced prostate cancer. Since its approval in 2010, Provenge has been administered to nearly 40,000 patients, demonstrating its impact on patient outcomes. In addition to its therapeutic offerings, Dendreon provides cellular therapy manufacturing services, supporting the development and commercialization of innovative cancer therapies. The company has a robust infrastructure that includes two cGMP manufacturing facilities and a strong logistics network, enabling them to deliver time-sensitive therapies efficiently. Dendreon's commitment to advancing cellular therapies is evident in their ongoing clinical trials and research initiatives aimed at expanding the applications of Provenge and other potential treatments.

9. PlantForm Corporation

• Website: plantformcorp.com
• Ownership type: Venture Capital
• Headquarters: Toronto, Ontario, Canada
• Employee distribution: Canada 91%, Brazil 9%
• Latest funding: Other (Grant), $25,000, February 2018
• Founded year: 2008
• Headcount: 11-50
• LinkedIn: plantform-corporation

PlantForm Corporation, based in Toronto, Ontario, is a biopharmaceutical company founded in 2008. The company is dedicated to the rapid development and production of specialty antibody and protein drugs through its proprietary _vivo_ XPRESS® technology platform. This plant-based system allows for the efficient production of biologics, including biosimilars and medical countermeasures, in a cost-effective manner. PlantForm's pipeline features notable products such as biosimilar versions of pembrolizumab (Keytruda®) and ranibizumab (Lucentis®), as well as innovative treatments for ricin exposure and nerve agent protection. The company has received funding, including a grant of $25,000 in 2018, which supports its ongoing research and development efforts. With a small team of 22 employees, PlantForm is positioned to serve pharmaceutical companies and research institutions that require effective biopharmaceutical solutions.

10. JHL Biotech

• Website: edenbiologics.com
• Ownership type: Corporate
• Headquarters: Zhubei, Hsinchu, Taiwan
• Latest funding: $50.0M, May 2022
• Founded year: 2012
• Headcount: 51-200
• LinkedIn: jhl-biotech

JHL Biotech, now operating as Eden Biologics, is a biopharmaceutical company based in Zhubei, Hsinchu, Taiwan. Established in 2012, the company focuses on developing biosimilars and providing contract development and manufacturing services to pharmaceutical and biotechnology firms. Eden Biologics aims to simplify the complexities involved in bringing biosimilar products to market, enhancing the availability of affordable biotechnology medicines globally. The company has a robust pipeline of proprietary biosimilars and has successfully navigated regulatory approvals in multiple countries. In 2022, Eden Biologics received $50 million in funding, reflecting strong investor interest. The company has also undergone significant changes, including the acquisition of its CDMO business unit by Bora Pharmaceuticals, which allows it to concentrate on its core mission of developing high-quality biologics. With a commitment to innovative manufacturing processes and a focus on quality, Eden Biologics is positioned to make a meaningful impact in the biopharmaceutical sector.

11. Pooyesh Darou Biopharmaceutical Co.

• Website: pooyeshdarou.com
• Ownership type: Private
• Headquarters: Tehran, Tehran, Iran
• Employee distribution: Iran 100%
• Founded year: 1997
• Headcount: 201-500
• LinkedIn: pooyesh-darou-biopharmaceutical-co

Pooyesh Darou Biopharmaceutical Co., founded in 1997 and based in Tehran, Iran, is a biotechnology company that specializes in the production of recombinant biopharmaceuticals. The company focuses on manufacturing therapeutic proteins that cater to unmet medical needs, serving both patients and healthcare providers. Pooyesh Darou operates under strict quality control measures and complies with international standards, ensuring that their products meet high safety and efficacy benchmarks. They have developed a range of recombinant proteins, including Granulocyte Colony Stimulating Factor and Erythropoietin, and maintain a significant market presence in Iran, holding about 80% of the biopharmaceutical market share. The company has established advanced manufacturing capabilities, including bacterial fermentation and cell culture facilities, and collaborates with reputable institutions for research and development. Their commitment to innovation and quality positions them as a significant contributor to the biopharmaceutical sector in the region.

12. Blau Farmacêutica

• Website: blau.com.br
• Ownership type: Private
• Headquarters: Cotia, Sao Paulo, Brazil
• Founded year: 1987
• Headcount: 1001-5000
• LinkedIn: blausiegel

Blau Farmacêutica, founded in 1987 and headquartered in Cotia, São Paulo, Brazil, is a prominent player in the pharmaceutical industry. The company focuses on high-complexity medications and biotechnology solutions, catering primarily to hospitals and healthcare providers across Latin America and the United States. Blau operates five manufacturing facilities in Brazil, equipped with advanced technology and adhering to stringent international regulatory standards. The company’s product portfolio includes essential medications in oncology, hematology, immunology, and other critical therapeutic areas. Blau is also involved in research and development, emphasizing innovative therapies that enhance patient care while minimizing side effects. With a commitment to quality and safety, Blau Farmacêutica is recognized for its contributions to the healthcare sector, making it a significant entity in the biopharmaceutical manufacturing space.

13. NPS Pharma

• Website: shire.com
• Ownership type: Corporate
• Headquarters: Bedminster, New Jersey, United States (USA)
• Employee distribution: United States (USA) 51%, Algeria 12%, Ireland 12%, Other 25%
• Latest funding: $86.4B, April 2018
• Founded year: 1986
• Headcount: 201-500
• LinkedIn: nps-pharmaceuticals

NPS Pharma, a subsidiary of Takeda Pharmaceutical Company Limited, is based in Bedminster, New Jersey. Founded in 1986, the company specializes in the research, development, manufacturing, and marketing of innovative medicines. NPS Pharma focuses on therapeutic areas that include gastrointestinal diseases, rare diseases, oncology, and vaccines. The company is dedicated to improving patient outcomes through its portfolio of pharmaceutical products. With a workforce of approximately 148 employees, NPS Pharma operates globally, contributing to Takeda's mission of transforming lives through advanced medical solutions. The company has received significant funding, amounting to over $86 billion, indicating strong investor confidence in its capabilities and future prospects.

14. Sanofi Belgium

• Website: sanofi.be
• Ownership type: Private
• Headquarters: Machelen, Flanders, Belgium
• Employee distribution: Belgium 99%
• Founded year: 2004
• Headcount: 501-1000
• LinkedIn: sanofi-belgium

Sanofi Belgium, established in 2004 and located in Machelen, Flanders, is a private pharmaceutical company that specializes in the research, development, and production of innovative medicines and therapies. With a workforce of approximately 1,600 employees across four sites in Belgium, Sanofi Belgium covers the entire pharmaceutical value chain. Their Geel facility is notable for producing therapeutic proteins from cell cultures, while their research and development site in Ghent is focused on developing NANOBODY® technology, a novel class of therapeutic proteins. Sanofi Belgium is committed to improving health outcomes for patients with chronic and rare diseases, and they actively engage in clinical studies to advance healthcare solutions. The company has made significant investments in its production capabilities, including a recent €120 million investment to enhance biopharmaceutical production at the Geel site, which is part of Sanofi's global manufacturing network.

15. MSD Sharp & Dohme GmbH

• Website: msd.de
• Ownership type: Private
• Headquarters: Amt Neuhaus, Lower Saxony, Germany
• Founded year: 2001
• Headcount: 1001-5000
• LinkedIn: msd-sharp-%26-dohme-gmbh

MSD Sharp & Dohme GmbH, a subsidiary of Merck & Co., Inc., is a pharmaceutical company based in Amt Neuhaus, Lower Saxony, Germany. Founded in 2001, the company specializes in the research, development, and manufacturing of medications and vaccines. MSD is particularly focused on addressing significant health challenges, with a strong emphasis on oncology and infectious diseases. Their product portfolio includes innovative therapies and vaccines aimed at improving patient outcomes and enhancing healthcare accessibility. MSD is dedicated to advancing global health through its commitment to sustainable practices and patient safety. The company operates several production facilities and is recognized as one of the major pharmaceutical manufacturers in Germany, contributing to both human and animal health through its extensive range of products.

16. Acceleron Pharma

• Website: acceleronpharma.com
• Ownership type: Corporate
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 94%, Canada 6%
• Latest funding: $11.5B, September 2021
• Founded year: 2003
• Headcount: 201-500
• LinkedIn: acceleron-pharma

Acceleron Pharma, founded in 2003 and based in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to developing innovative therapies for serious diseases. The company specializes in treatments for hematologic and pulmonary conditions, with a strong focus on improving patient outcomes through advanced research and development. Acceleron has made notable strides in its pipeline, particularly with therapies aimed at pulmonary arterial hypertension and beta-thalassemia. The company has received substantial funding, amounting to $115 million as of September 2021, which underscores investor confidence in its potential to deliver impactful treatments. With a workforce of around 201-500 employees, Acceleron is positioned as a significant player in the biopharmaceutical manufacturing sector, actively contributing to the development of specialized therapies.

17. IDT Biologika

• Website: idt-biologika.com
• Ownership type: Corporate
• Headquarters: Dessau-Roßlau, Saxony-Anhalt, Germany
• Employee distribution: Germany 87%, United States (USA) 12%
• Latest funding: $243.8M, June 2024
• Founded year: 1921
• Headcount: 1001-5000
• LinkedIn: idt-biologika-gmbh

IDT Biologika, founded in 1921 and headquartered in Dessau-Roßlau, Germany, operates as a contract development and manufacturing organization (CDMO) with a strong focus on the biopharmaceutical industry. The company specializes in the development and manufacturing of vaccines, cell and gene therapies, and other biologics. IDT Biologika serves a range of clients, including pharmaceutical and biotech companies, by providing expertise in regulatory compliance and high-quality production processes. With facilities in both Europe and North America, they offer end-to-end solutions for therapeutic product development. The company has invested significantly in its capabilities, with over €600 million allocated since 1993, including €400 million since 2011. Their commitment to quality is reflected in their strong regulatory track record, having received approvals from major authorities such as the EMA and FDA. IDT Biologika's recent funding of $243.75 million in June 2024 further underscores its active role in the biopharmaceutical sector, positioning it as a relevant player in the market.

18. ProBioGen AG

• Website: probiogen.de
• Ownership type: Corporate
• Headquarters: Berlin, Berlin, Germany
• Employee distribution: Germany 100%
• Latest funding: June 2010
• Founded year: 1994
• Headcount: 201-500
• LinkedIn: probiogen-ag

ProBioGen AG, based in Berlin, Germany, is a biopharmaceutical company founded in 1994. The firm specializes in contract development and manufacturing services, offering a comprehensive range of solutions that include GMP production, process development, and innovative technologies tailored for therapeutic proteins and antibodies. ProBioGen serves a clientele primarily composed of biotech and pharmaceutical companies, focusing on delivering reliable and efficient production processes. With a workforce of around 180 employees, the company has developed over 420 stable cell lines, showcasing its expertise in cell line engineering and process development. Their proprietary technologies, such as GlymaxX® for enhancing antibody potency and DirectedLuck® for transposase targeting, further illustrate their innovative approach. ProBioGen has established a strong reputation for quality and customer service, making it a trusted partner in the biopharmaceutical industry.

19. Biovac

• Website: biovac.co.za
• Ownership type: Corporate
• Headquarters: Cape Town, Western Cape, South Africa
• Employee distribution: South Africa 99%
• Latest funding: June 2016
• Founded year: 2003
• Headcount: 201-500
• LinkedIn: the-biovac-institute

Biovac is a biopharmaceutical company based in Cape Town, South Africa, founded in 2003. The company specializes in the development and manufacturing of vaccines, supplying over 15 million doses annually for the Expanded Programme on Immunisation in South Africa. Biovac is dedicated to enhancing local vaccine production capabilities, addressing the critical need for affordable vaccines in the region. Their manufacturing facilities adhere to current Good Manufacturing Practice (cGMP) standards, ensuring the quality and safety of their products. Biovac has established partnerships with various international organizations, including Sanofi Pasteur and Pfizer, to facilitate technology transfer and improve vaccine production processes. The company is also involved in developing regionally relevant vaccines, such as the Haemophilus influenzae type b (Hib) conjugate vaccine, and is committed to building local skills in the biopharmaceutical sector.

20. Sanyou Biopharmaceuticals Co., Ltd.

• Website: sanyoubio.com
• Ownership type: Private Equity
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Latest funding: Series B, August 2022
• Founded year: 2015
• Headcount: 201-500
• LinkedIn: sanyou-biopharmaceuticals-co-ltd

Sanyou Biopharmaceuticals Co., Ltd. is a biopharmaceutical company based in Cambridge, Massachusetts, with additional locations in China. Established in 2015, the company specializes in the research and development of innovative biological drugs. Sanyou offers a comprehensive range of services, including integrated R&D platforms, antibody development, and protein production. Their primary clientele consists of pharmaceutical companies and research institutions that seek advanced solutions for drug development. The company operates on a global scale, reflecting its ambition to contribute to the biopharmaceutical industry. Sanyou's focus on cutting-edge technologies and methodologies in drug development underscores its commitment to advancing healthcare solutions.

21. MedImmune

• Website: medimmune.com
• Ownership type: Venture Capital
• Headquarters: Gaithersburg, Maryland, United States (USA)
• Employee distribution: United States (USA) 78%, United Kingdom (UK) 18%, Other 4%
• Latest funding: $15.6B, April 2007
• Founded year: 1987
• Headcount: 1001-5000
• LinkedIn: medimmune

MedImmune, founded in 1987 and based in Gaithersburg, Maryland, is a biopharmaceutical company that operates as a subsidiary of AstraZeneca. It specializes in the research and development of innovative medicines across various therapeutic areas, including oncology, cardiovascular, and respiratory diseases. MedImmune is committed to improving health outcomes through its extensive pipeline of products. The company has a significant focus on sustainability and aims to address healthcare challenges through scientific innovation. With a workforce of approximately 960 employees, MedImmune contributes to AstraZeneca's overall mission of transforming healthcare and enhancing patient care globally.

22. Biosidus

• Website: biosidus.com.ar
• Ownership type: Private Equity
• Headquarters: Buenos Aires, Buenos Aires, Argentina
• Employee distribution: Argentina 88%, Colombia 6%, Mexico 2%, Other 4%
• Latest funding: June 2018
• Founded year: 1983
• Headcount: 501-1000
• LinkedIn: bio-sidus

Biosidus is a biotechnology firm based in Buenos Aires, Argentina, founded in 1983. The company specializes in the development and commercialization of biopharmaceuticals, with a strong emphasis on biosimilars. Operating manufacturing plants in Buenos Aires, Biosidus has expanded its reach to over 60 countries, catering to healthcare providers and patients alike. Their product offerings aim to enhance access to essential therapies, making a significant impact in markets across Latin America, Asia, Africa, and Eastern Europe. The company is committed to maintaining high international quality standards in its processes and products, which is evident in their adherence to various regulatory requirements. Biosidus also emphasizes research and development, continuously working on innovative solutions to improve patient care. Their operational scale, with around 482 employees, further supports their capacity to engage in biopharmaceutical manufacturing effectively.

23. MSD Switzerland

• Website: msd.ch
• Ownership type: Private
• Headquarters: Lucerne, Lucerne, Switzerland
• Employee distribution: Switzerland 96%, Germany 4%
• Founded year: 1963
• Headcount: 1001-5000
• LinkedIn: msdswitzerland

MSD Switzerland, officially known as MSD Merck Sharp & Dohme AG, is a biopharmaceutical company based in Lucerne, Switzerland. Founded in 1963, the company has dedicated itself to the discovery and development of innovative medications and vaccines. MSD focuses on critical health areas such as oncology, infectious diseases, and diabetes, striving to provide effective solutions to significant health challenges. The company operates a high-tech research and development center in Schachen, where it conducts numerous clinical studies across various therapeutic areas. MSD is committed to scientific research and has a strong pipeline of products aimed at improving patient outcomes. With a workforce of over 500 employees, MSD Switzerland plays a vital role in the local healthcare landscape, ensuring access to essential medications and vaccines for the Swiss population.

24. Dalas Biotech Limited

• Website: dalasbiotech.com
• Ownership type: Private
• Headquarters: Bhiwadi, Rajasthan, India
• Employee distribution: India 100%
• Founded year: 1989
• Headcount: 51-200
• LinkedIn: dalas-biotech-limited

Dalas Biotech Limited, based in Bhiwadi, Rajasthan, India, is a pharmaceutical and biotechnology company that has been in operation since 1989. The company focuses on the manufacturing and supply of healthcare products, catering primarily to healthcare providers and organizations. Dalas Biotech is committed to delivering high-quality pharmaceutical and biotechnology solutions that are essential for medical treatments. The company has established a reputation for its quality-driven approach and adherence to safety standards. It has also engaged in community health initiatives, such as setting up an oxygen plant during a health crisis and organizing vaccination camps. These activities reflect its commitment to social responsibility alongside its business operations.

Biopharmaceutical Manufacturing Insights: Key Companies

Want to Find More Biopharmaceutical Manufacturing Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!